New Zealand markets open in 1 hour 21 minutes
  • NZX 50

    12,197.15
    +44.95 (+0.37%)
     
  • NZD/USD

    0.6305
    -0.0024 (-0.38%)
     
  • ALL ORDS

    7,745.90
    -25.90 (-0.33%)
     
  • OIL

    74.11
    +0.72 (+0.98%)
     
  • GOLD

    1,882.70
    +6.10 (+0.33%)
     

The Worldwide Hemodialysis Industry is Expected to Reach $136 Billion by 2030

Company Logo
Company Logo

Hemodialysis Market

Hemodialysis Market
Hemodialysis Market

Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The "Hemodialysis Market Share, Size, Trends, Industry Analysis Report, By Product, By End-Use, By Dialysis Type, By Region, Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global Hemodialysis market size is expected to reach USD 136.86 billion by 2030, according to a new study. The report gives a detailed insight into the current market dynamics and provides analysis on future market growth.

ESRD and CKD have one of the greatest overall costs and healthcare service burdens. Renal failure and chronic kidney disease are becoming more common, which is one of the main drivers of market expansion. When one or both kidneys permanently stop functioning adequately, a patient has end-stage renal disease (ESRD), which necessitates long-term renal infusion therapy or a kidney transplant. Therefore, increasing ESRD prevalence is increasing the financial burden of kidney disorders globally and is a major driver of rising service revenue.

Further, it is anticipated that there will be a rise in the market demand for dialysis care due to the rising incidence of ESRD globally. As per the USRDS estimates, the highest prevalence of managed end-stage renal disease (ESRD) in 2018 was found in Jalisco, Mexico (594 pmp), Hungary (508 pmp), Taiwan (523 pmp), and the United States (395 pmp),.

Also, diabetes is a key contributor to ESRD globally. In 2018, diabetes was a contributing factor in more than half of all cases reported of treated ESRD in Singapore (66.4%), Malaysia (66.2%), Qatar (63.9%), and Hong Kong (52.0)

The rising prevalence of diabetes has increased ESRD, which has raised the market demand for dialysis and is the factor propelling the market growth over the forecast period. According to the International Diabetes Federation (IDF), there are currently 537 million persons living with diabetes worldwide.

In addition to this, the COVID-19 pandemic is expected to support the market's expansion during the coming years. This is primarily because of the active recommendations made by government agencies to perform surgery on COVID-19 patients who are in critical condition.

The Indian Government released guidelines regarding the dialysis process for COVID-19 patients, such as the state should designate and identify one facility with an adequate portion of trained staff, dialysis machines, water treatment systems, and other support types of equipment as a precaution in case the Covid-19 pandemic spreads further.

Hemodialysis Market Report Highlights

  • Home care segment is anticipated to grow at a significant CAGR over the forecast period due to the rise in market demand and increase in at-home healthcare consciousness among dialysis patients.

  • Hemodialysis segment accounted for a significant revenue share. The need for hemodialysis is also being driven by the clinical advantages of this technique, such as the shorter process time and acceptance of the arteriovenous fistula (AV Fistula).

  • Asia-Pacific is expected to grow at a significant CAGR over the projected period. The high incidence of diabetes and hypertension, the existence of high discretionary money, and the high adoption rate of technologically improved items are all contributing to these developing reasons.

  • The global players include with a global presence including Asahi Kasei Corporation, AWAK Technologies Inc., Allmed Medical Care Corporation, Nipro Corporation, Nikkiso Co., Ltd., Outset Medical, Inc., Quanta Dialysis Technologies, Toray Medical Co. Ltd., and Teleflex, Inc

Report Attribute

Details

No. of Pages

118

Forecast Period

2022 - 2030

Estimated Market Value (USD) in 2022

$79.64 billion

Forecasted Market Value (USD) by 2030

$136.86 billion

Compound Annual Growth Rate

7.0%

Regions Covered

Global

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Hemodialysis Market Insights
4.1. Hemodialysis - Industry Snapshot
4.2. Hemodialysis Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Increasing number of ESRD patients
4.2.1.2. Growing prevalence of diabetes and hypertension
4.2.2. Restraints and Challenges
4.2.2.1. Risks and complications of dialysis
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Hemodialysis Market Industry Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Hemodialysis Market, by Product
5.1. Key Findings
5.2. Introduction
5.2.1. Global Hemodialysis Market, by Product, 2018 - 2030 (USD Billion)
5.3. Device
5.3.1. Global Hemodialysis Market, by Device, by Region, 2018 - 2030 (USD Billion)
5.3.2. Machine
5.3.2.1. Global Hemodialysis Market, by Machine, by Region, 2018 - 2030 (USD Billion)
5.3.3. Dialyzer
5.3.3.1. Global Hemodialysis Market, by Dialyzer, by Region, 2018 - 2030 (USD Billion)
5.3.4. Water treatment system
5.3.4.1. Global Hemodialysis Market, by Water treatment system, by Region, 2018 - 2030 (USD Billion)
5.3.5. Others
5.3.5.1. Global Hemodialysis Market, by Others, by Region, 2018 - 2030 (USD Billion)
5.4. Consumables
5.4.1. Global Hemodialysis Market, by Consumables, by Region, 2018 - 2030 (USD Billion)
5.4.2. Bloodline
5.4.2.1. Global Hemodialysis Market, by Bloodline, by Region, 2018 - 2030 (USD Billion)
5.4.3. Concentrates
5.4.3.1. Global Hemodialysis Market, by Concentrates, by Region, 2018 - 2030 (USD Billion)
5.4.4. Catheters
5.4.4.1. Global Hemodialysis Market, by Catheters, by Region, 2018 - 2030 (USD Billion)
5.4.5. Others
5.4.5.1. Global Hemodialysis Market, by Others, by Region, 2018 - 2030 (USD Billion)
5.5. Service
5.5.1. Global Hemodialysis Market, by Service, by Region, 2018 - 2030 (USD Billion)

6. Global Hemodialysis Market, by Dialysis Type
6.1. Key Findings
6.2. Introduction
6.2.1. Global Hemodialysis Market, by Dialysis Type, 2018 - 2030 (USD Billion)
6.3. Hemodialysis
6.3.1. Global Hemodialysis Market, by Hemodialysis, by Region, 2018 - 2030 (USD Billion)
6.3.2. Conventional hemodialysis
6.3.2.1. Global Hemodialysis Market, by Conventional hemodialysis, by Region, 2018 - 2030 (USD Billion)
6.3.3. Short daily hemodialysis
6.3.3.1. Global Hemodialysis Market, by Short daily hemodialysis, by Region, 2018 - 2030 (USD Billion)
6.3.4. Nocturnal hemodialysis
6.3.4.1. Global Hemodialysis Market, by Nocturnal hemodialysis, by Region, 2018 - 2030 (USD Billion)
6.4. Peritoneal dialysis
6.4.1. Global Hemodialysis Market, by Peritoneal dialysis, by Region, 2018 - 2030 (USD Billion)
6.4.2. Continuous Ambulatory Peritoneal Dialysis (CAPD)
6.4.2.1. Global Hemodialysis Market, by Continuous Ambulatory Peritoneal Dialysis (CAPD), by Region, 2018 - 2030 (USD Billion)
6.4.3. Automated Peritoneal Dialysis (APD)
6.4.3.1. Global Hemodialysis Market, by Automated Peritoneal Dialysis (APD), by Region, 2018 - 2030 (USD Billion)

7. Global Hemodialysis Market, by End-Use
7.1. Key Findings
7.2. Introduction
7.2.1. Global Hemodialysis Market, by End-Use, 2018 - 2030 (USD Billion)
7.3. Home-based
7.3.1. Global Hemodialysis Market, by Home-based, by Region, 2018 - 2030 (USD Billion)
7.4. Hospital-based
7.4.1. Global Hemodialysis Market, by Hospital-based, by Region, 2018 - 2030 (USD Billion)

8. Global Hemodialysis Market, by Geography

9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles
10.1. Asahi Kasei Corporation
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. AWAK Technologies Inc
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Allmed Medical Care Corporation
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. AngioDynamics LLC
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. B. Braun Melsungen AG
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. Becton
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Dickinson & Company
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Baxter International
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Dialife S.A
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Fresenius SE & Co.
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development
10.11. KGaA
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Recent Development
10.12. Hemoclean Co., Ltd
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Benchmarking
10.12.4. Recent Development
10.13. Medtronic Plc
10.13.1. Company Overview
10.13.2. Financial Performance
10.13.3. Product Benchmarking
10.13.4. Recent Development
10.14. Nipro Corporation
10.14.1. Company Overview
10.14.2. Financial Performance
10.14.3. Product Benchmarking
10.14.4. Recent Development
10.15. Nikkiso Co., Ltd
10.15.1. Company Overview
10.15.2. Financial Performance
10.15.3. Product Benchmarking
10.15.4. Recent Development
10.16. Outset Medical, Inc
10.16.1. Company Overview
10.16.2. Financial Performance
10.16.3. Product Benchmarking
10.16.4. Recent Development
10.17. Quanta Dialysis Technologies
10.17.1. Company Overview
10.17.2. Financial Performance
10.17.3. Product Benchmarking
10.17.4. Recent Development
10.18. Toray Medical Co. Ltd
10.18.1. Company Overview
10.18.2. Financial Performance
10.18.3. Product Benchmarking
10.18.4. Recent Development
10.19. Teleflex, Inc
10.19.1. Company Overview
10.19.2. Financial Performance
10.19.3. Product Benchmarking
10.19.4. Recent Development

For more information about this report visit https://www.researchandmarkets.com/r/n684iu

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900